Leukogene Therapeutics, Inc. is a cancer biotherapeutics company delivering innovative immunotherapies for patients living with cancer. Our MHC class II targeted M2T™
immunotherapies direct and mobilize the immune system to eliminate tumor cells.
MHC II — the immune system’s GPS
Major Histocompatibility Complex class II (MHCII) are essential immune signaling molecules found on antigen presenting cells (APCs). They direct immune cells to their final destination by teaching them to seek out specific protein antigens and eliminate cells that express them. These are typically pathogenic cell types (think bacterial infection) but can sometimes be cells of the human host.
Tumor-associated antigens — a molecular address
Tumor-associated antigens (TAA) are proteins that are highly expressed on tumor cells and serve as molecular landmarks for immune cells. Our M2T™ immunotherapy platform programs immune cells to seek out and destroy cancer cells that express a specific TAA.
M2T™ guides the way
M2T™ binds tightly to MHCII and hijacks its normal function and communication with immune effector cells. Immune cells are programmed to attack TAAs and the cancer cells that express them.
Final destination
Once activated by M2T™ molecules, immune cells navigate to tumor sites that are rich in tumor-associated antigen (TAA) proteins. Upon arrival and recognition of their TAA target, immune cells are activated and multiply. They target and eliminate tumor cells, bringing their journey — and the cancer — to its end.
M2T™ Overview and Advantages
